Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a

Sun ,Zhan; Yan ,Bin; Yu ,Wen Yan; Yao ,Xueping; Ma ,Xiaojuan; Sheng ,Geli; Ma ,Qi

doi:10.3892/etm.2016.3518

Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a

Authors:
- Zhan Sun
- Bin Yan
- Wen Yan Yu
- Xueping Yao
- Xiaojuan Ma
- Geli Sheng
- Qi Ma
View Affiliations

Affiliations: Laboratory of Functional Experimentation, Preclinical College, Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China, Department of Otorhinolaryngology, Ürümqi First People's Hospital, Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China, Department of Pathophysiology, Preclinical College, Xinjiang Medical University, Ürümqi, Xinjiang 830054, P.R. China, Department of Geriatrics, Xinjiang National Clinical Research Base of Traditional Chinese Medicine, Xinjiang Medical University, Ürümqi, Xinjiang 830000, P.R. China
Published online on: July 13, 2016 https://doi.org/10.3892/etm.2016.3518
Pages: 1879-1884

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Doxorubicin (DOX) is one of the most effective chemotherapeutic drugs. However, its clinical use has been hampered due to the development of cardiotoxicity. Vitexin, which is the active ingredient of hawthorn leaf extract, has various biological activities, including antioxidant and anti‑inflammatory actions. The present study aimed to investigate whether vitexin was able to protect against DOX‑induced acute cardiotoxicity in model rats and the mechanisms of this protective effect were assessed. Adult Sprague‑Dawley rats were randomly assigned into the control (saline only), model (DOX only) and vitexin‑treated (DOX plus vitexin) groups. Rats in the model and vitexin‑treated groups were injected with DOX (2 mg/kg; i.p.) once a week for 4 weeks. Rats in the vitexin‑treated group were administered 30 mg/kg oral vitexin once daily at doses for 4 weeks. The levels of lactate dehydrogenase, creatine kinase isoenzyme-MB, malondialdehyde, superoxide dismutase, catalase and myeloperoxidase were assessed using assay kits. The levels of inflammatory mediators, including tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6, nuclear factor (NF)‑κB, and caspase-3, were assayed by the enzyme‑linked immunosorbent assay method. Western blot analysis was performed to assess the protein expression levels of p‑FOXO3a. Vitexin pretreatment significantly protected against DOX‑induced myocardial damage, which was characterized by increased serum creatine kinase isoenzyme‑MB and lactate dehydrogenase. Vitexin significantly ameliorated oxidative stress injury evoked by DOX, demonstrated by the inhibition of lipid peroxidation and the elevation of antioxidant enzyme activities. Furthermore, DOX provoked inﬂammatory responses by increasing the expression levels of IL‑1β, IL‑6, NF‑κB and tumor necrosis factor‑α, whereas vitexin pretreatment significantly inhibited these inﬂammatory responses. Notably, DOX induced apoptotic tissue damage by increasing caspase‑3 activity, whereas vitexin administration was able to decrease caspase-3 activity. In addition, vitexin induced elevated FOXO3a protein expression levels in the vitexin-treated group. In conclusion, the findings of the present study suggested that vitexin possesses cardioprotective action against DOX‑induced cardiotoxicity by suppressing oxidative stress, inflammation and apoptotic signals.

View Figures

View References

1	Poprach A, Petrakova K, Vyskoýil J, Lakomý R, Nċmeýek R, Kocak I, Kocakova I and Vyzula R: Cardiotoxicity of drugs used in oncology. Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti. 21:288–293. 2008.(In Czech). PubMed/NCBI
2	Jain D: Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol. 7:53–62. 2000. View Article : Google Scholar : PubMed/NCBI
3	Khan MA, Singh M, Khan MS, Ahmad W, Najmi AK and Ahmad S: Alternative approach for mitigation of doxorubicin-induced cardiotoxicity using herbal agents. Curr Clin Pharmacol. 9:288–297. 2014. View Article : Google Scholar : PubMed/NCBI
4	Nagai K, Fukuno S, Oda A and Konishi H: Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anticancer Drugs. 27:17–23. 2015. View Article : Google Scholar
5	Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J and Kalyanaraman B: Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochem J. 367:729–740. 2002. View Article : Google Scholar : PubMed/NCBI
6	Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E and Kotamraju S: Doxorubicin-induced apoptosis: Implications in cardiotoxicity. Mol Cell Biochem. 234-235:119–124. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ueno M, Kakinuma Y, Yuhki K, Murakoshi N, Iemitsu M, Miyauchi T and Yamaguchi I: Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci. 101:151–158. 2006. View Article : Google Scholar : PubMed/NCBI
8	van der Horst A and Burgering BM: Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 8:440–450. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, et al: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 10:138–148. 2008. View Article : Google Scholar : PubMed/NCBI
10	Yang W, Dolloff NG and El-Deiry WS: ERK and MDM2 prey on FOXO3a. Nat Cell Biol. 10:125–126. 2008. View Article : Google Scholar : PubMed/NCBI
11	Huang H and Tindall DJ: Dynamic FoxO transcription factors. J Cell Sci. 120:2479–2487. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH and Burgering BM: Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 419:316–321. 2002. View Article : Google Scholar : PubMed/NCBI
13	Marinkovic D, Zhang X, Yalcin S, Luciano JP, Brugnara C, Huber T and Ghaffari S: Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest. 117:2133–2144. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zick SM, Vautaw BM, Gillespie B and Aaronson KD: Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur J Heart Fail. 11:990–999. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wang XS, Hu XC, Chen GL, Yuan X, Yang RN, Liang S, Ren J, Sun JC, Kong GQ, Gao SG and Feng XS: Effects of vitexin on the pharmacokinetics and mRNA expression of CYP isozymes in rats. Phytother Res. 29:366–372. 2014. View Article : Google Scholar : PubMed/NCBI
16	Je HG, Hong SM, Je HD, Choi YS, Seo SY, Min YS, Chung SJ, Shin YK, Lee TJ, Park ES and Jeong JH: The inhibitory effect of vitexin on the agonist-induced regulation of vascular contractility. Pharmazie. 69:224–228. 2014.PubMed/NCBI
17	Tassell MC, Kingston R, Gilroy D, Lehane M and Furey A: Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev. 4:32–41. 2010. View Article : Google Scholar : PubMed/NCBI
18	Xue HF, Ying ZM, Zhang WJ, Meng YH, Ying XX and Kang TG: Hepatic, gastric, and intestinal first-pass effects of vitexin in rats. Pharm Biol. 52:967–971. 2014. View Article : Google Scholar : PubMed/NCBI
19	Lu CC, Xu YQ, Wu JC, Hang PZ, Wang Y, Wang C, Wu JW, Qi JC, Zhang Y and Du ZM: Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways. Naunyn-Schmiedeberg Arch Pharmacol. 386:747–755. 2013. View Article : Google Scholar
20	Flohe L and Otting F: Superoxide dismutase assays. Methods Enzymol. 105:93–104. 1984. View Article : Google Scholar : PubMed/NCBI
21	Sharma HS and Das DK: Role of cytokines in myocardial ischemia and reperfusion. Mediators Inflamm. 6:175–183. 1997. View Article : Google Scholar : PubMed/NCBI
22	El-Sayed EM, Mansour AM and Abdul-Hameed MS: Thymol and carvacrol prevent doxorubicin-induced cardiotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats. J Biochem Mol Toxicol. 30:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
23	Gao Y, Xu Y, Hua S, Zhou S and Wang K: ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress. Int J Clin Exp Med. 8:6794–6803. 2015.PubMed/NCBI
24	Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E and Tutuncu NB: Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf). 70:469–474. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ma Z, Ji W, Fu Q and Ma S: Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression. Inflammation. 36:1560–1566. 2013. View Article : Google Scholar : PubMed/NCBI
26	Munoz A and Costa M: Nutritionally mediated oxidative stress and inflammation. Oxid Med Cell Longev. 6109502013.PubMed/NCBI
27	Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI
28	Barnes PJ and Karin M: Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1066–1071. 1997. View Article : Google Scholar : PubMed/NCBI
29	Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G and Bauersachs J: Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovascular Res. 57:749–756. 2003. View Article : Google Scholar
30	Van der Heiden K, Cuhlmann S, le Luong A, Zakkar M and Evans PC: Role of nuclear factor kappaB in cardiovascular health and disease. Clinical Sci. 118:593–605. 2010. View Article : Google Scholar
31	Chen CT, Wang ZH, Hsu CC, Lin HH and Chen JH: In vivo protective effects of diosgenin against doxorubicin-induced cardiotoxicity. Nutrients. 7:4938–4954. 2015. View Article : Google Scholar : PubMed/NCBI
32	Gulimire A, Ybadaiti T, Rena K and Ting FW: Protective effect of total flavonoids of H. rhamnoides L. sunsp. Turkestanica rousi against adriamycin-induced cardiotoxicity in rats. Xin Jiang Yi Ke Da Xue Xue Bao. 33:383–385. 2010.
33	Dash SK, Chattopadhyay S, Ghosh T, Dash SS, Tripathy S, Das B, Bag BG, Das D and Roy S: Self-assembled betulinic acid protects doxorubicin induced apoptosis followed by reduction of ROS-TNF-alpha-caspase-3 activity. Biomed Pharmacother. 72:144–157. 2015. View Article : Google Scholar : PubMed/NCBI
34	Kim AD, Kang KA, Piao MJ, Kim KC, Zheng J, Yao CW, Cha JW, Hyun CL, Kang HK, Lee NH and Hyun JW: Cytoprotective effect of eckol against oxidative stress-induced mitochondrial dysfunction: involvement of the FoxO3a/AMPK pathway. J Cell Biochem. 115:1403–1411. 2014. View Article : Google Scholar : PubMed/NCBI